I averaged down from $20 to about $10 last week. The cash value of the shares is a little over $1 now. They have about 6 drugs in the pipeline now, 3-4 from the old company MHAN, 2 more from the 2010 merger (one is a great B-12 based product for tremors IIRC), and the new one from the recent R/M. Weise owns and controls about 50% of the common IIRC, and for him to step in buy at $2.25 was the signal I was waiting for to average down.
I think this one has an easy ride back to $5 to $6 once they start a road show promo for investors. They may even get it back to $10, which would be a $200 million dollar market cap, but that may be pushing it at this point in time. My plan is to average down to about $3-4, and try to sell at $5 to $6 down the road. I don't think they will have too much trouble walking it back up to $5. When they walk it back up, is another matter.
I think this one has an easy ride back to $5 to $6 once they start a road show promo for investors. They may even get it back to $10, which would be a $200 million dollar market cap, but that may be pushing it at this point in time. My plan is to average down to about $3-4, and try to sell at $5 to $6 down the road. I don't think they will have too much trouble walking it back up to $5. When they walk it back up, is another matter.
Ambition with out knowledge is like ship in dry dock. Going nowhere fast!
Recent TGTX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 09:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:25:41 AM
- TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:31:09 PM
- TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update • GlobeNewswire Inc. • 04/30/2026 11:30:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/29/2026 07:56:31 PM
- TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting • GlobeNewswire Inc. • 04/22/2026 11:30:00 AM
- TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI • GlobeNewswire Inc. • 04/15/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 08:33:42 PM
- TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis • GlobeNewswire Inc. • 03/09/2026 11:30:00 AM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting • GlobeNewswire Inc. • 03/06/2026 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2026 10:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:08:34 PM
- TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
- TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis • GlobeNewswire Inc. • 02/17/2026 12:30:00 PM
- TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis • GlobeNewswire Inc. • 02/08/2026 09:17:55 PM
- TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum • GlobeNewswire Inc. • 02/06/2026 12:30:00 PM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum • GlobeNewswire Inc. • 01/27/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2026 09:27:48 PM
- TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones • GlobeNewswire Inc. • 01/13/2026 09:25:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:16:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:15:33 PM
- TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/07/2026 12:30:00 PM
